PARPi

Phase 3Small molecule

SShanghai Gynecologic Oncology Group

PARPi is one of 85 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Ovarian CancerNot yet recruiting

Breast CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PARPi

SShanghai Gynecologic Oncology Group

Phase 3

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Ovarian Cancer

NCT04515602

Q3 2029

Phase 2Active, not recruiting

Breast Cancer

NCT05826964

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Active, not recruiting·UUniversity of Miami·Phase 2·NCT05826964·24 enrolled

HRD1 trial

HRD Status Reference Standard Based on WGS

Completed·LLei Li··NCT06490380·100 enrolled

Brain Tumors1 trial

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04173104·5 enrolled

Ovarian Cancer1 trial

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Not yet recruiting·SShanghai Gynecologic Oncology Group·Phase 3·NCT04515602·410 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PARPi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PARPi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PARPi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Gynecologic Oncology Group

PARPi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2029

Trials by Indication[1]

Breast Cancer1 trial

HRD1 trial

Brain Tumors1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News